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In their important study, Yang and colleagues used the National Cancer Data B se to examine 
definitive therapy (prostatectomy or radiotherapy) among 400,000 patients who were diagnosed 
with intermediate-risk or high-risk prostate cancer between 2004 and 2012.1
On the 1 hand, less use of definitive prostate cancer treatment among patients who are least likely 
to benefit (ie, elderly, comorbid patients) argues against the widely held belief that we are 
overtreating patients with prostate cancer. Indeed, compared with men who received efinitive 
treatment, those who did not receive such treatment were more likely to die within 1 year of 
diagnosis, regardless of age or prostate cancer disease risk, suggesting that decision mak ng was 
reasonably aligned with life expectancy. An increasing comorbidity score also was associated with 
a lower likelihood of receiving definitive treatment, such that men who had 2 or more 
Charlson-Deyo comorbidity points had approximately one-half the odds of receiving definitive 
treatment compared with men who had no comorbidities.
 By using 
multivariable regression to adjust for patient and sociodemographic factors, those inve tigators 
observed that patients decreasingly received definitive treatment with increasing age and 
worsening comorbidity. Indeed, greater than 40% of patients aged >80 years did not receive 
definitive treatment with radiation or surgery. Moreover, one-half of patients aged 80 years with 
high-risk prostate cancer who did not receive definitive treatment went on to undergo receive
primary androgen-deprivation therapy (ADT) instead. In this editorial, the authors conclude that 
significant under treatment of unfavorable-risk prostate cancer in the elderly puts them at up to 
20% risk of prostate cancer-related death at 10 years. 
2
Conversely, Yang et al observed overtreatment of elderly patients through a different 
mechanism—a high rate of chemical castration with ADT as the primary treatment for many 
elderly patients with localized prostate cancer who were not treated definitively with radiation or 
surgery. With increasing age, patients were less likely to receive definitive treatment but more 
likely to be treated with primary ADT. Although receipt of primary ADT was more pronounced 
 The finding that sicker patients were 
less likely to receive definitive treatment for localized prostate cancer after taking into 
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among patients with high-risk, localized disease who did not receive definitive prostate cancer 
treatment (41%), 1 in 5 men with intermediate-risk disease who did not undergo definitive 
treatment also received primary ADT. Because the benefits of castration are associated primarily 
with advanced rather than localized disease, and because safer, effective treatment approaches, 
such as observation (ie, watchful waiting) or radiation therapy exist, the authors point out that 
these findings are troubling, citing decreased overall survival with primary ADT for localized 
prostate cancer and its notable harms (eg, metabolic syndrome, fractures, and cognitive, 
cardiovascular, and sexual dysfunction).
In patients who do not undergo definitive treatment for localized disease, the early versus delayed 
castration dilemma has been studied in randomized trials. For example, European Organization for 
Research and Treatment of Cancer trial EORTC 30891 randomized 985 men with newly 
diagnosed T0-T4 N0-N2 M0 prostate cancer who were not candidates for local therapy, or who 
declined definitive therapy, to receive ADT either immediately or upon symptomatic disease 
progression or serious complications (ie, pathologic fracture, paralysis).
3 
4 The median age was 73 
years (range, 52-81 years), and the median prostate-specific antigen (PSA) level was 16 ng/mL 
(range, 0.2-1306.7 ng/mL). That study excluded men aged ≥80 years and those with regional 
lymph nodes or ureteral obstruction, and deferr d treatment was not reflexively initiated based on 
rising PSA or alkaline phosphatase levels, new bone scan hot spots, or soft tissue metastases. 
Patients were followed with rectal examinations, and PSA and alkaline phosphatase levels 
obtained at 6-month intervals for 2 years and then annually until death, with further evaluation for 
suspected progression. After a median follow-up of 7.8 years, 541 of 985 men died (52.2% 
immediate treatment vs 57.6% deferred treatment; hazard ratio, 1.25; 95% confidence interval, 
1.05-1.48). There were no differences in time to progression to castration-res stant disease or 
prostate cancer-specific survival, the median time to the start of deferred treatment was 7 years, 
and 25.6% of deferred patients never needed treatment. It is noteworthy that, within the first 5 
years, there were 187 deaths in the deferred treatment group (38%; 62 prostate cancer-related) 
versus 153 deaths in the immediate treatment group (31%; 42 prostate cancer-related), indicating 
that greater than one-third of the cohort had died within 5 years. These rates are higher than current 
survival estimates for localized prostate cancer and indicate a broad range of disease severity other 
than localized (eg, PSA >1000 ng/mL). A 12-year update of that trial demonstrated no differences 















This article is protected by copyright. All rights reserved 
men who died within 3 to 5 years.5 The average patient time on ADT was 27 months versus 87 
months for the deferred versus immediate treatment groups (P < .001), respectively, indicating 
approximately 5-year differences in ADT exposure. Fractures were rare in both groups. There was 
an overall survival advantage to immediate treatment, par icularly for men with PSA levels >50 
ng/mL and PSA doubling times <12 months.6 This finding suggests that immediate ADT may be a 
preferred option in these very-high-risk patients who decline or are not candidates for local 
treatment.5 However, most observational studies of primary ADT use for localized prostate cancer 
have demonstrated no survival advantage for primary ADT in localized disease7-9
Elderly men who are not able to undergo or who refuse definitive treatment for intermediate-risk 
and high-risk, localized prostate cancer have decisions to make in consultation with their 
providers. Specifically, are the risks and benefits of castration with ADT worth it? Should they 
pursue an observational approach with delayed treatment for symptomatic and/or metastatic 
progression that is unlikely to occur in their lifetime? As highlighted in the article, current 
management options offer minimal support for using ADT as the primary treatment in localized 
prostate cancer. The National Comprehensive Cancer Network guidelines indicate that<zaq;2> 
patients who have clinically localized prostate cancer should not receive ADT as monotherapy, 
perhaps except in cases of very high-risk disease among patients who are not eligible for other 
treatments as an alternative to observation (ie, watchful waiting).
; nd, in some 
patients (eg, those with longer life expectancy and low-risk disease), worse overall survival has 
been reported among those who received primary ADT. 
The disconnect between the greater use of primary ADT in patients who have the least to gain (or 
lose) with respect to life expectancy may signify a lack of tools to enable providers to effectively 
counsel patients about the misperception that ADT monotherapy is of value in their care. If we 
examine reasons for ADT initiation among patients in the deferred group from the EORTC 30891 
trial, then symptomatic progression with or without objective evidence accounted for over 
one-half (55%), whereas asymptomatic rises in markers (26.5%) and asymptomatic objective 
evidence (10.2%) accounted for much less.
3 
4 Arguably, it is likely that most patients with localized 
prostate cancer who received primary ADT in the current National Cancer Data Base tudy were 
asymptomatic and thus unlikely to have symptomatic progression given US screening practices 
and lead times. Therefore, primary ADT was probably received to avoid “doing nothing” among 
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For elderly men whose combination of life expectancy and prostate cancer risk favors treatment, 
an alternative to primary ADT to avoid doing nothing is to offer definitive radiotherapy. 
Radiotherapy has proven efficacy in high-risk patients,10 as pointed out by the authors, and referral 
to a radiation oncologist for counseling11
The de-implementation of low-value castration among men with localized prostate cancer 
continues to pose significant challenges rooted in the history of ADT and the concept that “less is 
more.” Since the discovery that prostate cancer cells depend on androgens by Huggins and Hodges 
in the 1940s,
 among men who might otherwise receive primary ADT 
may simultaneously decrease low-value primary ADT use and increase appropriate treatment for 
men who may otherwise die of their disease. 
12 castration strategies have become the primary choice of initial therapy for men with 
advanced and symptomatic prostate cancer, with spillover effects into the treatment of 
asymptomatic, localized disease in which little to no benefits exist. Although the harms of ADT 
are increasingly recognized,13
This concept—beliefs about consequences—is a key domain in the theoretical domains 
framework
 they may be underappreciated by providers and patients seeking to 
treat localized disease in lieu of definitive treatments, helping to drive the observed treatment 
patterns. In other words, competing beliefs about consequences of treating men who have 
localized prostate cancer using primary ADT—the consequences of both receiving and not 
receiving ADT—may be playing a significant role in the observed treatment patterns. 
14
An interesting phase 2 trial recently demonstrated that rapid cycling between high and low serum 
testosterone concentrations was beneficial for some men with castrate-resis ant disease.
 of individual behavior change and, more broadly, may be a powerful contributor to 
the overuse of cancer care by providers and patients. For primary ADT in most men with localized 
disease, minimizing beliefs about the harmful consequences of receiving primary ADT sets up an 
exchange of temporarily lowering PSA levels, providing false hope to patients and providers that 
men will live longer and better lives, with near-guaranteed quality-of-life impairments and little to 
no overall survival advantage. Conversely, mphasizing beliefs about the positive consequences of 
not receiving primary ADT challenges our current belief structures about the inevitability of 
prostate cancer progression to symptomatic, metastatic disease and the idea that earlier and more 
effective castration is better. Clarifying this pervasive tension appears warranted to guide the 
development of effective strategies focused on curbing the overuse of low-value prostate cancer 
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than removing testosterone altogether (eg, primary ADT), this “bipolar” approach also challenges 
dogma that “less is more" with regard to the complex relation between testosterone and prostate 
cancer. Better understanding patient and provider beliefs about the consequences of receiving or 
not receiving primary ADT in localized disease is needed. Both patients and providers will have to 
overcome yet unknown psychological barriers to recognize that de-implementation of low-value 
chemical castration and follow-up with observation can be an appropriate strategy for the 
preservation of the quality and quantity of life for older men with localized prostate cancer. 
In summary, the study by Yang and colleagues demonstrated the potential underuse of definitive 
surgery or radiation for men with intermediate-risk and high-risk, localized prostate cancer; 
however, perhaps just as important, the results also highlighted the widespread overuse of primary 
ADT monotherapy among many of these same men. Maximizing the quality and quantity of life 
among patients with localized prostate cancer who are elderly and have competing comorbidities 
may be achieved more effectively either by treating these patients definitively or by opting for 
observation rather than primary ADT. A better understanding of the optimal ways to de-implement 
this low-value cancer care appears to be warranted both for elderly patients, who have little to gain 
by it, and for younger patients, who have more to lose by foregoing definitive treatment with 
surgery or radiation therapy. 
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Maximizing the quality and quantity of life among men with localized prostate cancer who are 
elderly and have competing comorbidities may be achieved more effectively, either by treating 
these patients definitively or by opting for observation rather than using primary 
androgen-deprivation therapy. A better understanding of the optimal ways to de-implement this 
low-value cancer care appears to be warranted for both elderly patients, who have little to gain by 
it, and younger patients, who have more to lose by foregoing definitive treatment with surgery or 
radiation therapy. 
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Maximizing quality and quantity of life among patients with localized prostate cancer 
who are elderly and have competing comorbidities may be achieved more effectively by 
either treating these patients definitively or opting for observation, rather than using 
primary ADT. Better understanding optimal ways to de5implement this low value cancer 
care appears warranted for both elderly patients who have little to gain by it, and 














































































younger patients with more to lose by foregoing definitive treatment with surgery or 
radiation therapy. 
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In this important study, Yang et al. used the National Cancer Database (NCDB) 
to examine definitive therapy (prostatectomy or radiotherapy) among 400,000 patients 
diagnosed with intermediate or high risk prostate cancer between 2004 and 2012.1 
Using multivariable regression to adjust for patient and sociodemographic factors, the 
investigators found decreasing definitive treatment with increasing age and worsening 
comorbidity. In fact, more than 40% of patients over 80 years did not receive definitive 
treatment with radiation or surgery. Moreover, half of patients over 80 years old with 
high risk prostate cancer who did not receive definitive treatment went on to undergo 
primary androgen deprivation therapy (ADT) instead. The authors conclude that 
significant undertreatment of unfavorable risk prostate cancer in the elderly puts them at 
up to 20% risk of prostate cancer5related death at 10 years. 
On the one hand, less use of definitive prostate cancer treatment among patients 
who are least likely to benefit (i.e., elderly, comorbid patients) argues against the widely 
held belief that we are overtreating patients with prostate cancer. Indeed, compared 
with men undergoing definitive treatment, those men who did not receive definitive 
treatment were more likely to die within one year of diagnosis, regardless of age or 
prostate cancer disease risk, suggesting that decision5making was reasonably aligned 
with life expectancy. Increasing comorbidity score was also associated with a lower 
likelihood of receiving definitive treatment such that men with two or more Charlson5
Deyo comorbidity points had approximately half the odds of receiving definitive 
treatment compared to men with no comorbidities.2 The fact that sicker patients were 
less likely to receive definitive treatment of localized prostate cancer after taking into 
consideration other factors (e.g., demographics) was an encouraging finding. 














































































On the other hand, the authors found overtreatment of elderly patients through a 
different mechanism—a high rate of chemical castration with ADT as the primary 
treatment for many elderly patients with localized prostate cancer who were not treated 
definitively with radiation or surgery. Patients with increasing age were less likely to 
receive definitive treatment, but more likely to be treated with primary ADT. While being 
treated with primary ADT was more pronounced in patients with high risk localized 
disease who did not receive definitive prostate cancer treatment (41%), one in five men 
with intermediate risk disease not undergoing definitive treatment was also treated with 
primary ADT. Given the fact that the benefits of castration are primarily associated with 
advanced rather than localized disease, and safer, effective treatment approaches such 
as observation (i.e., watchful waiting) or radiation therapy exist, the authors point out 
that these findings are ‘troubling’ citing decreased overall survival with primary ADT for 
localized prostate cancer, and its notable harms (e.g., metabolic syndrome, fractures, 
cognitive, cardiovascular, and sexual dysfunction).3  
In patients not undergoing definitive treatment for localized disease, the early 
versus delayed castration dilemma has been studied in randomized trials. For example, 
EORTC 30891 randomized 985 men with newly diagnosed T054 N052 M0 prostate 
cancer who were not candidates for local therapy, or declined definitive therapy, to 
receive ADT either immediately or upon symptomatic disease progression or serious 
complications (i.e., pathologic fracture, paralysis).4 The median age was 73 years 
(range 52581) and PSA 16 (range 0.251306.7) This study excluded men ≥80 years, 
those with regional lymph nodes or ureteral obstruction, and deferred treatment was not 
reflexively initiated based on rising PSA or alkaline phosphatase, new bone scan hot 














































































spots, or soft tissue metastases. Patients were followed with rectal exams, PSA and 
alkaline phosphatase levels obtained at 6 month intervals for 2 years, and then annually 
until death with further evaluation for suspected progression. After a median follow up of 
7.8 years, 541 of 985 men died (52.2% immediate vs. 57.6% deferred, hazard ratio 
1.25, 95% CI 1.05 to 1.48). There were no differences in time to progression to 
castration5resistant disease or prostate cancer5specific survival, with the median time to 
start deferred treatment of 7 years, and 25.6% of deferred patients never needing 
treatment. Interestingly, within the first five years, there were 187 deferred treatment 
group deaths (38%, 62 prostate cancer5related) vs. 153 immediate treatment group 
deaths (31%, 42 prostate cancer5related) indicating that over one5third of the cohort had 
died within 5 years. These rates are higher than current survival estimates for localized 
prostate cancer, and indicate a broad range of disease severity other than localized 
(e.g., PSA >1,000). A 125year update of this trial demonstrated no differences in time to 
castration resistance or prostate cancer5specific mortality, with the exception of those 
men dying within 355 years.5 The average patient time on ADT was 27 months vs. 87 
months for the deferred vs. immediate groups (p<0.001), respectively, indicating 
approximately 5 year differences in ADT exposure. Fractures were rare in both groups. 
There was an overall survival advantage to immediate treatment particularly for men 
with PSA>50 ng/mL and PSA doubling times <12 months.6 This finding suggests that 
immediate ADT may be a preferred option in these very high risk patients who decline 
or are not candidates for local treatment.5 However, most observational studies of 
primary ADT use for localized prostate cancer have demonstrated no survival 
advantage for primary ADT in localized disease,759 and in some cases (e.g., longer life 
expectancy and low risk disease), worse overall survival among those treated with 















































































Elderly men not able to undergo or refusing definitive treatment for intermediate 
and high risk localized prostate cancer have decisions to make in consultation with their 
providers. Namely, are the risks and benefits of castration with ADT worth it? Should 
they pursue an observational approach with delayed treatment for symptomatic and/or 
metastatic progression that is unlikely to occur in their lifetime? As highlighted in the 
article, current management options offer minimal support for using ADT as the primary 
treatment in localized prostate cancer. The National Comprehensive Cancer Network 
guidelines state: “ADT should not be used as monotherapy in clinically localized 
prostate cancer,” perhaps except in cases of very high risk disease among patients not 
eligible for other treatments as an alternative to observation (i.e., watchful waiting).3  
The disconnect between the higher use of primary ADT in those patients with the 
least to gain (or lose) with respect to life expectancy may signify a lack of tools to 
enable providers to effectively counsel patients about the misperception that ADT 
monotherapy is of value in their care. If we examine reasons for ADT initiation among 
patients in the deferred group of EORTC 30891, symptomatic progression with or 
without objective evidence accounted for over half (55%), while asymptomatic rises in 
markers (26.5%) and asymptomatic objective evidence (10.2%) accounted for much 
less.4 Arguably, it is likely that most patients with localized prostate cancer treated with 
primary ADT in the current NCDB study were asymptomatic and thus unlikely to have 
symptomatic progression given US screening practices and lead times. Therefore, 
primary ADT was probably given to avoid ‘doing nothing’ among asymptomatic men 
with localized prostate cancer and provided them more harms than benefits. For elderly 














































































men whose combination of life expectancy and prostate cancer risk favors treatment, an 
alternative to giving primary ADT to avoid ‘doing nothing’ is to offer definitive 
radiotherapy. Radiotherapy has proven efficacy in high risk patients,10 as pointed out by 
the authors, and referral to a radiation oncologist for counseling11 among men who 
might otherwise receive primary ADT may simultaneously decrease low value primary 
ADT use, and increase appropriate treatment of men who may otherwise die of their 
disease.  
De5implementation of low value castration among men with localized prostate 
cancer continues to pose significant challenges rooted in the history of ADT and the 
concept that ‘less is more.’ Since the discovery of prostate cancer cells’ dependence on 
androgens by Huggins and Hodges in the 1940s,12 castration strategies have become 
the primary choice of initial therapy for men with advanced and symptomatic prostate 
cancer, with spillover effects into treatment of asymptomatic localized disease where 
little to no benefits exist. While the harms of ADT are increasingly recognized,13 they 
may be underappreciated by providers and patients seeking to treat localized disease in 
lieu of definitive treatments, and helping to drive the observed treatment patterns. In 
other words, competing 	ABC	DEADC of treating men with localized 
prostate cancer with primary ADT, both the consequences of giving and not giving ADT, 
may be playing a significant role in the observed treatment patterns.  
This concept, 	ABC	DEADCFis a key domain in the Theoretical 
Domains Framework14 of individual behavior change, and may be a powerful contributor 
to overuse of cancer care by providers and patients more broadly. For primary ADT in 
most localized disease, DD	ABBAC	DEADC	D














































































 sets up an exchange of temporarily lowering PSA levels providing false5
hope to patients and providers that men will live longer and better lives, with near5
guaranteed quality of life impairments and little to no overall survival advantage. 
Conversely, D	ABB	BC	DEADC 	D	BD
 challenges our current belief structures about the inevitability of prostate cancer 
progression to symptomatic metastatic disease, and that earlier and more effective 
castration is better. Clarifying this pervasive tension appears warranted to guide 
development of effective strategies focused on curbing overuse of low value prostate 
cancer care, and working collaboratively with older patients to optimize care and quality 
of life. 
Interestingly, a recent phase II trial demonstrated that rapid cycling between high 
and low serum testosterone concentrations was beneficial for some men with castrate5
resistant disease.15 Rather than removing testosterone altogether (e.g., primary ADT), 
this ‘bipolar’ approach also challenges dogma that ‘less is more’ in the case of 
testosterone’s complex relationship with prostate cancer. Better understanding patient 
and provider 	ABBC	DEADC of giving or not giving primary ADT in 
localized disease is needed. Both patients and providers will have to overcome yet 
unknown psychological barriers in order to recognize that de5implementation of low 
value chemical castration, and follow up with observation, can be an appropriate 
strategy for the preservation of the quality and quantity of life of older men with localized 
prostate cancer. 
In summary, this study demonstrated the potential underuse of definitive surgery 
or radiation for men with intermediate and high risk localized prostate cancer, but 














































































perhaps as important, also showed the widespread overuse of primary ADT 
monotherapy among many of these same men. Maximizing quality and quantity of life 
among patients with localized prostate cancer who are elderly and have competing 
comorbidities may be achieved more effectively by either treating these patients 
definitively or opting for observation, rather than using primary ADT. Better 
understanding optimal ways to de5implement this low value cancer care appears 
warranted for both elderly patients who have little to gain by it, and younger patients 
with more to lose by foregoing definitive treatment with surgery or radiation therapy.   
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